NLRC5

Across TCGA pan-cancer cohorts, NLRC5 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NLRC5 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NLRC5 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NLRC5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and LUAD are the cancer types where NLRC5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.182	0.635	.002	17	view →
LSCC	DFS	Median	All	1.000	0.482	.002	8	view →
LUAD	DFS	Median	All	0.838	0.407	.014	4	view →
HNSC	DFS	Median	IV	0.848	0.556	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NLRC5–PDAC (DFS)

Open the PDAC breakdown →